

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: HALKIER et al. Conf.:  
Appl. No.: NEW Group: 1647  
Filed: Examiner: DEBERRY, REGINA  
For: METHOD FOR DOWN-REGULATING  
OSTEOPROTEGERIN LIGAND ACTIVITY

INFORMATION DISCLOSURE STATEMENT  
(SUBMISSION WITH CONTINUATION-IN-PART OR  
RULE 1.53(b) CONTINUATION OR DIVISIONAL APPLICATION)

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

September 16, 2003

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications, or other information submitted for consideration by the Office are listed on the PTO-1449 form(s), attached hereto.

II. REFERENCES PREVIOUSLY CITED OR SUBMITTED

Pursuant to 37 C.F.R. § 1.98(d), consideration of information listed on the PTO-1449 form(s) is requested since any patents, publications, or other information which are listed on the PTO-1449 form(s) but for which copies are not enclosed herewith, were previously cited by or submitted to the PTO in one of the following applications which has been relied upon for an earlier filing date under 35 U.S.C. § 120:

U.S. Appl. No(s).  
09/396,937

U.S. Filing Date(s)  
September 15, 2003

III. FEES


This Information Disclosure Statement is being filed concurrent with the filing of a continuation-in-part, continuation, or divisional patent application; therefore, no fee is required.

If the Examiner has any questions concerning this IDS or requires a copy of any of the references cited but not provided, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule and charge the appropriate fee to Deposit Account No. 02-2448.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fee required under 37 C.F.R. §§ 1.16 or 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

 By *Kalpana Kelly* #46,183  
Leonard R. Svensson, #30,330

P.O. Box 747  
Falls Church, VA 22040-0747  
(703) 205-8000

LRS/KR/sml  
4614-0120P

Attachment(s) : ☒ PTO-1449(s)

☐ References

☐ Foreign Search Report

☐ Other:

(Rev. 04/29/03)

(Use several sheets if necessary)

APPLICATION NO.  
NEW

FILING DATE

|       |      |
|-------|------|
| GROUP | 1647 |
|-------|------|

## U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

**OTHER DOCUMENTS** (Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.

Kuby, J. Immunology, Second Edition, pp 85-108, Freeman and Company, New York 1994

J. Immunology 1996, 157:4796-4804 Dalum et al. "Breaking of B Cell Tolerance Toward a Highly Conserved Self Protein"

J. Exp. Med., Vol. 188 No. 5, Spetember 7, 1998, 997-1001, Fuller et al. "TRANCE Is Necessary and Sufficient for Osteoblast-Mediated Activation of. . ."

J. Cell Biology, Vol. 145 No. 3, May 3, 1999, 527-38, Burgess et al. "The Ligand for Osteoprotegerin (OPGL) Directly Activates Mature Osteoclasts"

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Use several sheets if necessary)

APPLICATION NO.  
NEW

FILING DATE

|       |      |
|-------|------|
| GROUP | 1647 |
|-------|------|

[illegible][illegible]

**OTHER DOCUMENTS** (Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.)

ANDERSON et al., "A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function", Nature, Vol. 390, 13 November 1997, pp. 175-179

EXAMINER

|                 |
|-----------------|
| DATE CONSIDERED |
|-----------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Use several sheets if necessary)

|       |
|-------|
| GROUP |
| 1647  |

[illegible][illegible]

## OTHER DOCUMENTS

RIGGS et al, "Proposed Standard Nomenclature of New Tumor Necrosis Factor Family Members Involved in the Regulation of Bone Resorption", Journal of Bone and Mineral Research, Vol. 15, November 12, 2000, pp. 2293-2296

EXAMINER

DATE CONSIDERED

LRS/KR/sml